GO:1990715 mRNA CDS binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990715 (mRNA CDS binding) describes the molecular function of proteins that selectively recognize the coding sequence (CDS) of messenger RNA, a process that controls mRNA stability, translation, and decay.
• m6A and m5C modifications within the CDS act as recruitment platforms for reader proteins such as YTHDF2 and YBX1, directly linking CDS binding to mRNA fate decisions.
• N4BP1 is a well-characterized CDS-binding protein that degrades mRNA substrates independently of nonsense-mediated decay, highlighting the specificity of CDS recognition.
• CDS binding influences translation efficiency and protein output, with subcytoplasmic localization of translation adding an additional layer of spatial control.
• The exon junction complex shapes the m6A epitranscriptome and can modulate CDS accessibility, indirectly affecting CDS-binding events.
• Dysregulation of CDS-binding proteins is implicated in cancers such as esophageal squamous cell carcinoma, gastric cancer, and hepatocellular carcinoma.
Description
The Gene Ontology term GO:1990715, mRNA CDS binding, defines the selective interaction of a protein with the coding sequence (CDS) of an mRNA molecule. Unlike binding to untranslated regions, CDS binding positions regulatory factors directly on the protein-coding portion of the transcript, where they can influence translation elongation, mRNA stability, and decay. This function is emerging as a central node in post-transcriptional gene regulation, particularly because chemical modifications within the CDS, such as N6-methyladenosine (m6A) and 5-methylcytosine (m5C), serve as docking sites for reader proteins. Researchers study mRNA CDS binding to understand how cells achieve precise control of protein output under normal and pathological conditions. For example, m6A sites in the CDS can trigger translation-dependent mRNA decay, a process that directly couples the act of translation with transcript elimination. Similarly, the NEDD4-binding protein N4BP1 recognizes CDS elements to degrade mRNA substrates through a mechanism independent of nonsense-mediated decay, revealing an alternative route for transcript turnover. These findings underscore the importance of CDS binding in shaping the transcriptome and proteome. Dysregulation of CDS-binding proteins has been linked to cancer progression. YBX1 promotes esophageal squamous cell carcinoma by stabilizing SMOX mRNA in an m5C-dependent manner, while hypoxia-inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent regulation of CBS in gastric cancer. In hepatocellular carcinoma, N4-acetylcytidine modification and eEF2-mediated HMGB2 mRNA translation are emerging as critical events. Thus, understanding mRNA CDS binding offers mechanistic insights and potential therapeutic targets across multiple malignancies.
mRNA CDS binding At A Glance
| GO ID | GO:1990715 |
|---|---|
| GO term | mRNA CDS binding |
| Ontology | biological_process |
| Synonym | None |
| Major function | Selective binding to the coding sequence of mRNA to regulate translation, stability, and decay |
| Related modifications | m6A, m5C, N4-acetylcytidine within the CDS |
| Key reader proteins | YTHDF2, YBX1, N4BP1, eEF2 |
| Associated diseases | Esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma |
| Research methods | Ribo-seq, RNA-seq, CLIP-seq, proteomics, imaging |
What Is GO:1990715?
mRNA CDS binding (GO:1990715) is a molecular function that describes the selective, non-covalent interaction of a protein or protein complex with the coding sequence (CDS) of an mRNA. The CDS is the portion of the mRNA that is translated into protein, and binding to this region allows regulatory factors to directly influence translation and mRNA stability. This function is distinct from binding to untranslated regions or to general RNA sequences, as it requires recognition of specific sequence or structural features within the CDS. Proteins with this activity often act as readers of RNA modifications, such as m6A or m5C, that are embedded within the CDS.
Why Is mRNA CDS binding Important in Cell Biology?
mRNA CDS binding is important because it provides a direct mechanism for coupling the translation of a transcript to its stability and decay. Proteins that bind the CDS can sense the translational status of an mRNA and trigger its degradation if necessary, as shown for m6A sites in the CDS that induce translation-dependent decay. This function also allows cells to rapidly adjust protein output in response to stress, hypoxia, or oncogenic signals. Because CDS-binding proteins are frequently deregulated in cancer, they represent promising targets for therapeutic intervention.
• Controls mRNA stability by recruiting decay machinery to the coding sequence.
• Regulates translation efficiency and protein output in response to cellular cues.
• Integrates chemical modifications (m6A, m5C) into post-transcriptional gene regulation.
• Plays a role in cancer progression, including esophageal, gastric, and liver cancers.
• Provides a mechanism for translation-dependent mRNA decay, linking translation and turnover.
• Influences ferroptosis through m6A-YTHDF2-dependent modulation of CBS.
• Shapes the m6A epitranscriptome via the exon junction complex.
• Offers potential biomarkers and therapeutic targets in oncology.
• Enables precise control of protein output through subcytoplasmic localization.
• Facilitates degradation of mRNA substrates independent of nonsense-mediated decay.
What Happens During mRNA CDS binding?
Recognition of CDS elements
In simple terms: Proteins scan the mRNA and lock onto specific sequences within the coding region.
The first step in mRNA CDS binding is the recognition of sequence or structural features within the coding sequence. These features can include modified nucleotides such as m6A or m5C, which serve as docking sites for reader proteins. For example, YTHDF2 recognizes m6A sites in the CDS of CBS mRNA, leading to its modulation in gastric cancer. Similarly, YBX1 binds m5C-modified SMOX mRNA to promote its stabilization in esophageal squamous cell carcinoma. The exon junction complex can also shape the m6A epitranscriptome, thereby influencing which CDS sites are available for binding.
Recruitment of regulatory complexes
In simple terms: Once bound, the protein recruits other factors that decide the mRNA's fate.
After binding to the CDS, the protein often serves as a platform to recruit additional regulatory complexes. For instance, N4BP1 binds mRNA substrates through the coding sequence and targets them for degradation independently of nonsense-mediated decay. This recruitment can lead to mRNA decay, translational repression, or enhanced translation, depending on the context. In hepatocellular carcinoma, N4-acetylcytidine modification within the CDS recruits eEF2 to HMGB2 mRNA, repressing its translation and suppressing tumor progression.
Translation-dependent mRNA decay
In simple terms: When the mRNA is being translated, CDS-binding proteins can mark it for destruction.
A key outcome of CDS binding is translation-dependent mRNA decay. m6A sites in the coding region can trigger decay only when the mRNA is actively translated, coupling protein synthesis to transcript turnover. This mechanism ensures that aberrant or unnecessary transcripts are eliminated efficiently. The subcytoplasmic location of translation further controls protein output, as the spatial context of translation can influence whether CDS-bound factors promote decay or stabilization.
Regulation of protein output
In simple terms: CDS binding fine-tunes how much protein is made from each mRNA.
By binding to the CDS, regulatory proteins can directly modulate translation elongation and termination. For example, eEF2-mediated translation of HMGB2 mRNA is repressed by N4-acetylcytidine in the CDS, reducing protein output. This layer of control allows cells to rapidly adjust protein levels without changing mRNA abundance. The interplay between CDS-binding proteins and the translation machinery thus determines the final proteome landscape.
Integration with cellular stress and hypoxia
In simple terms: CDS binding helps cells respond to stress by altering mRNA fate.
Under hypoxia, the lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent regulation of CBS, highlighting how CDS binding integrates with stress responses. Similarly, metabolic reprogramming in MASH-HCC involves CD36 regulation, which may intersect with CDS-binding pathways. These examples illustrate that mRNA CDS binding is not a static process but is dynamically regulated by environmental cues.
Key Genes Involved in GO:1990715 mRNA CDS binding
The following genes and proteins are experimentally implicated in mRNA CDS binding or its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| YBX1 | Binds m5C-modified CDS to stabilize SMOX mRNA | Promotes esophageal squamous cell carcinoma progression |
| YTHDF2 | Recognizes m6A in CDS to modulate mRNA stability | Involved in gastric cancer ferroptosis via CBS regulation |
| N4BP1 | Degrades mRNA substrates through CDS binding | Functions independently of nonsense-mediated decay |
| eEF2 | Translation elongation factor recruited to CDS | Mediates N4-acetylcytidine-dependent repression of HMGB2 |
| HMGB2 | Target of CDS-mediated translational repression | Suppresses hepatocellular carcinoma progression |
| CBS | Regulated by m6A-YTHDF2 in CDS | Modulates ferroptosis in gastric cancer |
| SMOX | Stabilized by YBX1 via m5C in CDS | Contributes to esophageal cancer progression |
| CD36 | Metabolic regulator potentially linked to CDS binding | Involved in MASH-HCC progression |
| EJC components | Shape m6A epitranscriptome | Influence CDS accessibility for reader proteins |
| m6A writers | Deposit m6A in CDS | Create docking sites for YTHDF2 |
| m5C writers | Deposit m5C in CDS | Create docking sites for YBX1 |
| NAT10 | Catalyzes N4-acetylcytidine modification | Enhances eEF2 binding to HMGB2 CDS |
| Ribosome | Translates CDS and interacts with CDS-bound factors | Couples translation to mRNA decay |
| UPF1 | Nonsense-mediated decay factor | Distinct from N4BP1-mediated CDS degradation |
| IGF2BP proteins | Potential m6A readers in CDS | May stabilize transcripts |
| HNRNP proteins | RNA-binding proteins that can bind CDS | Modulate splicing and stability |
How Is mRNA CDS binding Regulated?
mRNA CDS binding is regulated at multiple levels. The deposition of chemical modifications such as m6A and m5C within the CDS is controlled by writer enzymes and can be influenced by the exon junction complex. Reader proteins such as YTHDF2 and YBX1 are themselves subject to post-translational modifications and abundance changes. Additionally, the subcytoplasmic localization of translation can determine whether CDS-bound factors promote decay or stabilization. Cellular stress, including hypoxia, can alter the expression of lncRNAs that modulate CDS binding.
mRNA CDS binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| YBX1 | Esophageal squamous cell carcinoma | Knockout or overexpression in esophageal cancer cell lines |
| YTHDF2 | Gastric cancer ferroptosis | Knockout in gastric cancer cells under hypoxia |
| N4BP1 | mRNA decay independent of NMD | Knockout in HEK293 or HeLa cells |
| eEF2 | Hepatocellular carcinoma | Point mutation or knockout in liver cancer cells |
| CD36 | MASH-HCC progression | Overexpression in hepatocyte models |
mRNA CDS binding in cancer
Dysregulation of mRNA CDS binding is increasingly recognized in cancer. YBX1 promotes esophageal squamous cell carcinoma progression by stabilizing SMOX mRNA in an m5C-dependent manner. In gastric cancer, hypoxia-inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent regulation of CBS. Hepatocellular carcinoma progression is suppressed by targeting N4-acetylcytidine, which represses eEF2-mediated HMGB2 mRNA translation. These examples demonstrate that CDS-binding proteins can act as oncogenes or tumor suppressors depending on context.
mRNA CDS binding in metabolic liver disease
LIX1L aggravates MASH-HCC progression by reprogramming hepatic metabolism and the microenvironment via CD36. Although direct CDS binding to CD36 mRNA has not been fully characterized, the intersection of metabolic regulation and RNA modification pathways suggests that CDS-binding proteins may contribute to liver disease progression. Further research is needed to establish direct links.
mRNA CDS binding and translation-dependent decay
m6A sites in the coding region trigger translation-dependent mRNA decay, a process that can be hijacked in disease to eliminate tumor-suppressive transcripts. N4BP1 degrades mRNA substrates through the coding sequence independent of nonsense-mediated decay, providing an alternative decay pathway that may be altered in cancer. Understanding these mechanisms could lead to new therapeutic strategies.
From mRNA CDS binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of YBX1 affect SMOX mRNA stability? | YBX1 knockout in esophageal cancer cells |
| Does m6A in CDS trigger decay? | Point mutation of m6A sites in CDS of reporter mRNA |
| Is N4BP1-mediated decay NMD-independent? | N4BP1 knockout with UPF1 knockdown |
| Does YTHDF2 binding to CBS CDS modulate ferroptosis? | YTHDF2 knockout in gastric cancer cells |
| Does N4-acetylcytidine affect HMGB2 translation? | Knock-in of acetylated cytidine in HMGB2 CDS |
| Does subcytoplasmic translation affect protein output? | Tagged knock-in of ribosomes for imaging |
How to Study the mRNA CDS binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Ribosome occupancy and translation efficiency | Detecting translation-dependent decay |
| RNA-seq | mRNA abundance and splicing | Quantifying changes in transcript levels |
| CLIP-seq | Protein-RNA binding sites at nucleotide resolution | Mapping CDS binding of YTHDF2 or YBX1 |
| Proteomics | Protein expression levels | Validating changes in protein output |
| m6A-seq | Global m6A modification sites | Identifying m6A in CDS |
| m5C-seq | Global m5C modification sites | Identifying m5C in CDS |
| Single-molecule FISH | Localization of specific mRNAs | Studying subcytoplasmic translation |
| Polysome profiling | Association of mRNA with ribosomes | Measuring translation status |
Ribo-seq and RNA-seq
Ribosome profiling (Ribo-seq) combined with RNA-seq allows researchers to measure translation efficiency and mRNA abundance simultaneously. This is particularly useful for studying CDS binding because it can reveal whether binding events lead to changes in translation or decay. For example, m6A sites in the CDS trigger translation-dependent decay, which can be detected by comparing ribosome occupancy and mRNA levels.
CLIP-seq and related techniques
Crosslinking and immunoprecipitation followed by sequencing (CLIP-seq) enables mapping of protein-RNA interactions at nucleotide resolution. This method can identify exact CDS regions bound by proteins such as YTHDF2 or YBX1. When combined with modification-specific antibodies, it can reveal how m6A or m5C marks guide CDS binding.
Proteomics and translation profiling
Mass spectrometry-based proteomics can quantify changes in protein output following manipulation of CDS-binding proteins. This is essential for understanding how CDS binding affects the proteome. For instance, repression of HMGB2 translation by N4-acetylcytidine can be monitored by proteomics.
Imaging and spatial analysis
Advanced imaging techniques, such as single-molecule FISH and live-cell imaging of translation, can reveal the subcytoplasmic localization of CDS binding and translation. These methods help determine whether CDS-bound factors act in specific cellular compartments.
How CRISPR Can Be Used to Study GO:1990715 mRNA CDS binding
Knockout
CRISPR knockout of genes encoding CDS-binding proteins, such as YBX1 or YTHDF2, allows researchers to assess their loss-of-function phenotypes. For example, YBX1 knockout reduces SMOX mRNA stability and impairs esophageal cancer cell progression. Similarly, YTHDF2 knockout alters CBS regulation and ferroptosis in gastric cancer.
Point Mutation
Point mutations can be introduced into the CDS of target mRNAs to disrupt or create binding sites for regulatory proteins. For instance, mutating m6A sites in the CDS of a reporter mRNA can prevent YTHDF2 binding and block translation-dependent decay. This approach precisely dissects the contribution of individual nucleotides to CDS binding.
Knock-in
Knock-in of tagged versions of CDS-binding proteins or of modified nucleotides in the CDS enables visualization and biochemical analysis. Tagged knock-in of ribosomal proteins can reveal subcytoplasmic translation sites. Knock-in of N4-acetylcytidine in the HMGB2 CDS can mimic the modification and study its effect on eEF2 binding.
Overexpression
Overexpression of CDS-binding proteins or their target mRNAs can reveal gain-of-function effects. Overexpression of YBX1 enhances SMOX mRNA stabilization and promotes cancer progression. Overexpression of N4BP1 accelerates degradation of CDS-containing substrates.
How EDITGENE Supports mRNA CDS binding Research
Researchers studying mRNA CDS binding-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer progression or metabolic dysregulation. CRISPR-based models provide a robust way to establish causality by precisely manipulating genes and their regulatory elements.
Contact EDITGENE today to design your custom CRISPR model for mRNA CDS binding research.
Frequently Asked Questions About mRNA CDS binding
What is mRNA CDS binding?
mRNA CDS binding (GO:1990715) is the selective interaction of a protein with the coding sequence of an mRNA, regulating its translation, stability, and decay.
What genes are involved in mRNA CDS binding?
Key genes include YBX1, YTHDF2, N4BP1, and eEF2, which recognize modified nucleotides or sequence elements within the CDS.
How does mRNA CDS binding affect translation?
It can either enhance or repress translation. For example, N4-acetylcytidine in the CDS recruits eEF2 to repress HMGB2 translation, while m6A sites can trigger translation-dependent decay.
What diseases are linked to mRNA CDS binding?
Dysregulation is implicated in esophageal squamous cell carcinoma, gastric cancer, and hepatocellular carcinoma.
What methods are used to study mRNA CDS binding?
Common methods include Ribo-seq, CLIP-seq, RNA-seq, proteomics, and imaging techniques.
How can CRISPR help study mRNA CDS binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes and CDS elements to test their function.
Is mRNA CDS binding the same as mRNA binding?
No, mRNA CDS binding specifically refers to binding within the coding sequence, whereas general mRNA binding can occur anywhere on the transcript.
What is the role of m6A in mRNA CDS binding?
m6A within the CDS serves as a docking site for reader proteins like YTHDF2, which can trigger translation-dependent decay.
Can mRNA CDS binding be targeted therapeutically?
Yes, targeting CDS-binding proteins or their modifications is being explored in cancer therapy, such as inhibiting N4-acetylcytidine to suppress hepatocellular carcinoma.
What cell models are available for mRNA CDS binding research?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for genes involved in mRNA CDS binding.
Conclusion
mRNA CDS binding (GO:1990715) is a critical molecular function that governs post-transcriptional gene regulation by coupling translation to mRNA stability and decay. Proteins such as YBX1, YTHDF2, and N4BP1 recognize modified nucleotides or sequence elements within the coding sequence to control transcript fate. This function is frequently dysregulated in cancer and metabolic diseases, making it an attractive target for therapeutic intervention. Advances in CRISPR-based models, Ribo-seq, and CLIP-seq are accelerating our understanding of CDS binding mechanisms. EDITGENE offers a comprehensive suite of services, including knockout, point mutation, knock-in, overexpression, and CRISPR library screening, to support researchers in dissecting the roles of CDS-binding proteins in health and disease.
References
- 1. Liu L et al.. 2024. YBX1 Promotes Esophageal Squamous Cell Carcinoma Progression via m5C‐Dependent SMOX mRNA Stabilization.. Adv Sci (Weinh) 11(20):e2302379 PMID: 38566431
- 2. Zhou Y et al.. 2024. m6A sites in the coding region trigger translation-dependent mRNA decay.. Mol Cell 84(23):4576-4593.e12 PMID: 39577428
- 3. Zheng W et al.. 2024. The NEDD4-binding protein N4BP1 degrades mRNA substrates through the coding sequence independent of nonsense-mediated decay.. J Biol Chem 300(12):107954 PMID: 39491646
- 4. Yang H et al.. 2022. Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer.. J Adv Res 37:91-106 PMID: 35499052
- 5. Liu H et al.. 2024. Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.. Cancer Commun (Lond) 44(9):1018-1041 PMID: 39030964
- 6. Horste EL et al.. 2023. Subcytoplasmic location of translation controls protein output.. Mol Cell 83(24):4509-4523.e11 PMID: 38134885
- 7. Yang X et al.. 2022. Exon junction complex shapes the m(6)A epitranscriptome.. Nat Commun 13(1):7904 PMID: 36550132
- 8. Leng Y et al.. 2025. LIX1L aggravates MASH-HCC progression by reprogramming of hepatic metabolism and microenvironment via CD36.. Pharmacol Res 211:107567 PMID: 39725340
